INTRODUCTION
The endocytosis of extracellular molecules and plasma membrane proteins is required by cells to internalize nutrients, down-regulate receptors, and remove damaged proteins from the membrane. Primary endocytic vesicles that form at the plasma membrane transfer these components to an early endosome where some proteins are sorted for recycling back to the plasma membrane. Others continue through the endosomal pathway to the late endosome/prelysosome and then to the lysosome where they are degraded.
*Present address: Department of Biochemistry, Molecular Biology, and Cell Biology, Northwestem University, 2153 Sheridan Road, Evanston, IL 60208. Membrane transport through the mammalian endocytic pathway has been studied in vivo and in vitro, and some of the proteins that function in endosomal transport have been identified (reviewed by Gruenberg and Maxfield, 1995) . Many of these are proteins similar to those that mediate membrane transport in the secretory pathway. A number of small GTP-binding proteins are localized to the plasma membrane and endosomal compartments. Members of the Rab/ Ypt family function in recycling to the plasma membrane and in lysosome-directed transport at the early and late endosomes (Simons and Zerial, 1993; SingerKruger et al., 1994; Feng et al., 1995) . Members of the ARF family have been localized to early endocytic compartments and the plasma membrane (D'SouzaSchorey et al., 1995; Peters et al., 1995; Whitney et al., 1995) . Heterotrimeric G proteins have been suggested i 1997 by The American Society for Cell Biology to be required for the fusion of early endosomes in vitro (Colombo et al., 1992 ). An ATPase, the N-ethylmaleimide-sensitive fusion protein (NSF) is also required in vitro for the fusion of early endosomes with each other (Diaz et al., 1989; Rodriguez et al., 1994) and another class of proteins with proposed fusogenic functions, the annexins, have also been implicated in endosomal transport (Gruenberg and Emans, 1993) . Coatomer (COPI) proteins that mediate vesicle budding in the biosynthetic pathway have recently been found associated with endosomes and are required for the formation of endocytic carrier vesicles in vitro (Whitney et al., 1995; Aniento et al., 1996) . Finally, phosphatidylinositide-3 (PI-3) kinases appear to regulate the transport of both secretory and endocytosed proteins destined for the lysosome (De Camilli et al., 1996) .
The association of proteins known to be required for vesicle budding and fusion in the secretory pathway with endocytic compartments suggests that some transport steps in the endocytic pathway are also mediated by vesicular transport. However, compared with the secretory pathway, inward transport via endosomes to the lysosome is not well characterized and controversy still exists about which transport steps are mediated by vesicles and which may occur through organelle maturation and fusion.
To provide more information about how endosomal transport occurs at the molecular level, we have studied the endocytic pathway of Saccharomyces cerevisiae. This yeast internalizes small molecules by both fluid phase and receptor-mediated endocytosis (Riezman, 1993) . Proteins similar to those endocytosed in mammalian cells, including nutrient permeases, G-proteincoupled receptors, and peptide transporters, are internalized from the plasma membrane and transported to the vacuole where they are degraded. Endosomal transport in yeast can be studied by monitoring radioactively labeled a-factor pheromone that is bound and internalized by its G-protein-coupled receptor, Ste2p. Internalized a-factor-Ste2p complex does not recycle but is degraded in the vacuole. Degradation of internalized a-factor is inhibited by energy poisons that block membrane traffic and is severely retarded at 15°C, a temperature at which endocytic traffic in mammalian cells is also slowed. On its way from the plasma membrane to the vacuole, a-factor moves through two biochemically separable membranebounded compartments known as the yeast early and late endosomes (Singer and Riezman, 1990) .
It has been previously shown that the endocytic and biosynthetic pathways to the vacuole overlap at the prevacuolar compartment, an organelle that accumulates vacuolar and endocytosed proteins in a subset of vacuolar protein sorting (vps) mutants (Piper et al., 1995) . This prevacuolar organelle may be one of the endocytic compartments that mediate the transport of a-factor. How proteins are transported between yeast endocytic compartments is not known, although several proteins that function in this process have been identified. These include the small GTP-binding proteins encoded by the YPT7 and VPS21/YPT51 genes (Wichmann et al., 1992; Schimmoller and Riezman, 1993;  Singer-Kruger et al., 1994; Horazdovsky et al., 1994) , the PI-3 kinase Vps34p (Munn and Riezman, 1994) , a dynamin homologue Dnmlp (Gammie et al., 1995) , and proteins encoded by the VPS2/REN1 and VPS4/END13 genes (Davis et al., 1993; Munn and Riezman, 1994) .
In this report we identify the yeast early and late endosomes morphologically, demonstrating that they are similar in character and distribution to mammalian endocytic organelles. We also demonstrate that the Secl8/NSF protein is required in vivo for an early postinternalization step leading to transport to the vacuole. Finally, we show that transport through the yeast early endosome requires an active secretory pathway, implying that endocytic traffic is tightly regulated by the delivery of some component from the early secretory organelles to the early endosome.
MATERIALS AND METHODS
Strains, Plasmids, Media, and Reagents vps2 (Tom Stevens, University of Oregon, Eugene, OR), erg6 (Rick Gaber, Northwestern University, Evanston, IL), and sec mutants (Randy Schekman, University of California, Berkeley, CA), except secl8-20, were crossed once or twice to RH448 to introduce barl-i into the strains. secl8-20 was isolated in a screen for mutants defective in the accumulation of a fluid-phase endocytic marker, lucifer yellow, in the vacuole (Chvatchko et al., 1986) . This mutant failed to secrete active invertase and did not complement secl8-1 but was complemented by the SEC18 gene carried on a plasmid. secl8-20 does not grow at 30°C, like secl8-1, and transport of newly synthesized carboxypeptidase Y (CPY) out of the endoplasmic reticulum (ER) is blocked at 32°C with no preincubation at this temperature (our unpublished data). pep4::URA3 derivatives of some sec strains were constructed by one-step gene disruption with pTS15 (Tom Stevens, University of Oregon). The genotypes of all strains are listed in Table 1. YPUAD-rich medium, SD minimal medium, and SDYE medium have been described (Zanolari et al., 1992; Hicke and Riezman, 1996) . EXPRE35S35S protein labeling mix was obtained from DuPont (Wilmington, DE). Recombinant lyticase was purified from Escherichia coli as described (Shen et al., 1991) with the following modifications: Osmotic shock fluid was dialyzed overnight in 10 mM sodium acetate (pH 5) and loaded onto a Mono S HR55 column (Pharmacia LKB Biotechnology, Uppsala, Sweden) on a Pharmacia FPLC system equilibrated in the same buffer, and lyticase activity was eluted with a 0-200 mM NaCl gradient in the sodium acetate buffer. Lyticase activity was eluted at "40 mM NaCl.
35S-labeled a-factor was purified as described (Singer and Riezman, 1990 ) and stored in a solution of 29.6% acetonitrile, 0.025% trifluoroacetic acid, 0.01% Triton X-100, and 10 ng/ml hemoglobin after freezing in liquid nitrogen. Reagents used in a-factor internalization and degradation assays and for the fractionation of endosomes by differential centrifugation and on Nycodenz gradients were obtained as described (Singer and Riezman, 1990 ). LEU2, pep4-3, ura3, leu2, his4, Iys2, barl-i RH2401 vps2, pep4, ura3, leu2, his4, barl-i RH3387 end4::HIS3, pep4, ura3, his3, suc2A, barl-i RH3205 end6-1, ura3::STE2-cymc[URA3], ura3, leu2, his4, Iys2, barl-i RH1491 secl2-4, ura3, leu2, his4, Iys2, barl-i RH2044 secl2-4, pep4::URA3, ura3, leu2, his4, Iys2, barl-i RH1737 secl8-20, ura3, leu2, his4, barl-i RH2043 secl8-20, pep4::URA3, ura3, leu2, his4, barl-I RH2465 secl2-4, sec18-20, ura3, leu2, his, barl-I RH1489 secl3-1, ura3, leu2, his4, lys2, barl-i RH1499 secl6-2, ura3, leu2, his4, lys2, barl-i RH1592 sec17-1, ura3, leu2, his4, Iys2, barl-i RH1486 sec20-1, ura3, leu2, his4, Iys2, barl-i RH1436 sec23-1, ura3, leu2, his4, barl-i RH1522 sec7-1, ura3, leu2, his4, barl-i RH1554 sec4-2, ura3, his4, lys2, barl-i RH1524 sec5, ura3, leu2, his4, lys2, barl-i RH1528 sec9, urq3, leu2, his4, Iys2, barl-i RH3415 retl-1, ura3, leu2, his, barl-I RH2688 sec27, ura3, leu2, his4, barl-i RH1885 erg6, ura3 , leu2, his4, barl-I a All strains listed are MATa.
The c-myc epitope EQKLISEEDLN was introduced into the second extracellular loop of Ste2p between amino acids T1" and Q200 by PCR mutagenesis as described . The sequence of the PCR-amplified part of the resulting plasmid was determined to ensure that the epitope had been introduced accurately with no additional mutations. The plasmid encoding the Ste2-c-myc protein was introduced into the ura3 gene of strain RH1298 (ste2A) by single-step gene transplacement. The Ste2-c-myc protein complemented the ste2A defect in a-factor response exhibited by the parent strain (as measured by mating projection formation) and internalized a-factor with kinetics identical to wild-type Ste2p.
CPY and affinity-purified Ste2p antiserum have been described (Hicke and Riezman, 1996) . Monoclonal antibody 9E10 that recognizes the c-myc epitope (Evan et al., 1985) Figure 7 , cells were then centrifuged and resuspended in 32°C YPUAD containing cycloheximide and incubation continued for 5 min at 32°C. Experiments with other strains did not include this step. An aliquot of cycloheximidetreated cells was withdrawn (10 ml) and the remaining cells were exposed to 1 X 10-7 M a-factor at 15-320C. Aliquots of cells (10 ml) were removed at various times, and all samples were fixed by the addition of 0.1 vol of 37% formaldehyde/I M potassium phosphate (pH 6.5) for 2 h at room temperature. Fixed cells were then washed three times with SP buffer (1.2 M sorbitol/0.1 M potassium phosphate, pH 6.5) and resuspended in 1.5 ml of SP containing 20 mM 2-mercaptoethanol and recombinant lyticase to remove the cell wall.
After lyticase treatment for 1 h at 30'C, the cells were washed three times with SP and finally resuspended in 0.25 ml of SP. Fixed cells were incubated with Ste2p antiserum and Cy3-conjugated secondary antibody and prepared for immunofluorescence as described (Zanolari and Riezman, 1991) .
For confocal microscopy cells were prepared as above except that end6 cells were preincubated for 15 min at 370C before the addition of cycloheximide, and incubation with cycloheximide, followed by the addition of a-factor, was continued at 370C. (110-nm thick) were cut on a Reichert-Jung Ultracut microtome with a FC4E cryoattachment. They were labeled with a c-myc monoclonal antibody and anti-mouse IgG conjugated to 5-or 10-nm gold particles (Biocell Research Laboratories, Cardiff, United Kingdom) and then contrasted and embedded as described (Nilsson et al., 1993) . The sections were stained with lead citrate and examined in a Zeiss EM10 electron microscope.
Pulse-Biosynthesis Analysis of Carboxypeptidase Y
The transport of CPY through the biosynthetic pathway was monitored by pulse-chase analysis performed as described (Hicke and Riezman, 1996) with the following modification: Cells were preincubated for 5 min at 32°C before the addition of 50 ,uCi of EXPRE35S35S protein labeling mixture, and incubation at 32°C was continued during the following pulse-chase period.
ae-Factor Internalization Assays
All assays were performed as described (Dulic et al., 1991) YPUAD, 10 ,ug/ml cycloheximide were added to one sample, and cells were incubated for 5 min at 30°C. 35S-labeled a-factor was added (2-5 x 106 cpm) and allowed to bind to cells for 5 min at 30°C. Unbound a-factor was removed by centrifugation at 30°C. Cells were then resuspended in 30 ml of YPUAD with or without cycloheximide and incubated with shaking at 30°C. After 0, 20, and 60 min, aliquots (10 ml) were removed and diluted into 90 ml of ice-cold sorbitol medium [0.8 M sorbitol/5 mM 2-amino-2-methyl-1,3-propanediol-piperazine-N,N'-bis(ethanesulfonic acid) buffered to pH 6.8 with PIPES] containing 10 mM NaN3 and 10 mM NaF. Cells from each time point were then converted to spheroplasts and lysed, and the resulting lysates were subjected to differential centrifugation as previously described (Singer and Riezman, 1990 ) with the following modification: To increase the recovery of endosomes in the 100,000 x g pellet (P3) fraction, spheroplasts were lysed in sorbitol medium by homogenization (six strokes, five to seven times) in a Wheaton tissue grinder fitted with an A pestle (Wheaton, Millville, NJ). The P3 fraction was resuspended in 1.6 ml of 37% (wt/vol) Nycodenz with four to six strokes in a Potter-Elvehjem homogenizer. The membranes in the resuspended pellet were then overlaid with Nycodenz solutions of decreasing density and centrifuged, and gradient fractions were collected as described (Singer and Riezman, 1990 ). The 100,000 x g supernatant (S3) resulting from this treatment was centrifuged overnight (15-16 h) at 150,000 x g in a TLA100 rotor fitted with microcentrifuge tube adapters (Beckman Instruments, Palo Alto, CA) to generate P4 pellet and S4 supernatant fractions.
To analyze endosomal transport in secl8 and wild-type strains, cells were harvested and washed as described above and then resuspended in 40 ml of YPUAD precooled on ice. 35S-labeled a-factor was added and allowed to bind to cells for 45 min to 1 h on ice with gentle rocking. Unbound a-factor was removed by centrifugation at 3°C for 4 min at 4000 x g in a GSA rotor (Beckman Instruments). Cells were resuspended in 40 ml of YPUAD prewarmed to 32°C and-incubated with shaking at 32°C. After 5, 15, 30, and 60 min, aliquots were removed. Lysates were prepared from each aliquot and subjected to differential centrifugation and Nycodenz gradient fractionation as described above.
To follow the transport of a-factor in secl2 and wild-type cells that had been preincubated at 32°C before internalization, cells were grown, harvested, and washed as described above. Cells were then resuspended in 40 ml of YPUAD prewarmed to 32°C, incubated for 5 min at 32°C, and 35S-labeled a-factor was added. Incubation with a-factor was continued for 5 min at 32°C to allow binding, and unbound peptide was removed by centrifugation at 32-34°C. The cell pellet was resuspended in 40 ml of 32°C YPUAD and incubation with shaking was continued at 32°C. Aliquots of cells (10 ml) were removed at 0, 15, 30, and 60 min of chase, converted to spheroplasts, and lysed. Differential centrifugation of the lysates and fractionation of P3 fractions on Nycodenz gradients was carried out as described above.
To test the effect of BFA on endosomal transport, an experiment similar to the previous one was performed on erg6 cells propagated at 30°C. After harvesting and washing, however, cells were resuspended in 30°C medium to which methanol or BFA in methanol (75 ,ug/ml, final concentration) had been added. Cells were then incubated for 5 min at 30°C; a-factor was added, allowed to bind for 5 min at the same temperature, and removed by centrifugation as described above. Cells were then resuspended in 30°C medium containing either BFA or methanol alone, and aliquots were removed after 10 and 60 min.
In each fractionation experiment, the extent of cell lysis was determined by analyzing the percent of the cytosolic protein hexokinase that was released into the SI supernatant. The amount of radioactivity found in pellet and supernatant fractions was expressed as a percent of the total radioactivity in the lysate after correction for cell lysis as described previously (Singer and Riezman, 1990 ). The profiles of radioactivity resulting from Nycodenz gradient fractionation were also normalized for the amount of cell lysis in each time point sample.
RESULTS
Transport of the ae-Factor Receptor through the Endocytic Pathway Two sequential membrane-bounded intermediates in the transport pathway from plasma membrane to vacuole have been identified by the fractionation of cell membranes (Singer and Riezman, 1990; Singer-Kruger et al., 1993) . These compartments have been designated the yeast early and late endosomes. To identify the yeast endosomes morphologically, we followed transport of the a-factor receptor through the pathway by performing immunofluorescence with anti-receptor antiserum. Cells were incubated with cycloheximide to inhibit new receptor synthesis and then exposed to a-factor to stimulate internalization of cellsurface Ste2p. Figure la shows that before the addition of a-factor to cells the receptor was found in an uneven distribution on the cell surface. In some cases it was also observed in small dot-like structures that appeared to be intracellular. This may be receptor that had been internalized constitutively and was en route through the endocytic pathway. Upon binding a-factor, all receptor was internalized and was observed at later time points in large structures that resided immediately adjacent to the vacuole. Staining of these compartments faded eventually (compare 16 and 30 min in the 30°C experiment), probably due to vacuolar degradation of the receptor. Staining of smaller more peripheral structures was seen at very early times after a-factor addition (4 min). As these small structures Molecular Biology of the Cell may be early compartments of the endocytic pathway, we attempted to visualize them more extensively by performing immunofluorescence on cells incubated at 15°C, a temperature that retards transport through endosomes. At 16 min after exposure of cells to pheromone at this temperature, the ring-like staining at the cell surface had disappeared and extensive staining was seen in a large number of small peripheral structures, as well as a larger perivacuolar dot. After longer times, the staining disappeared from the smaller organelles and concentrated in the large structure that resided next to the vacuole. These results are consistent with the idea that the receptor moves through small peripheral early organelles and then into a large perivacuolar late organelle before it enters the vacuole.
Receptor was not observed in the vacuole itself because it was rapidly degraded once it reached this organelle. To demonstrate visually that the final destination of Ste2p was the vacuole, we identified receptor by immunofluorescence in pep4 mutant cells that lack active vacuolar hydrolases. As the receptor undergoes slow constitutive endocytosis, we expected to find undegraded receptor in the vacuole and on the cell surface in the absence of a-factor. Figure lb demonstrates that this was the case. Upon treatment of pep4 cells with pheromone, the receptor disappeared from the cell surface and staining was seen only in the vacuole. To show that receptor that accumulated in the vacuole in pep4 cells arrived there through the endocytic pathway, and not through an aberrant biosynthetic pathway, a pep4end4A mutant was constructed. The end4A mutant is unable to internalize pheromone at any temperature and receptor remains at the cell surface even after a-factor binding (our unpublished data). In the pep4end4 double mutant, the receptor was visualized primarily at the cell surface both before and after the exposure of cells to pheromone, demonstrating that the accumulation of receptor in the vacuole in pep4 mutants required its internalization from the plasma membrane.
The perivacuolar structure in which receptor was observed after a-factor binding and internalization is strikingly similar to the prevacuolar compartment in which newly synthesized vacuolar proteins accumulate in a subset of mutants that are defective in vacuolar protein sorting (vps mutants) (Raymond et al., 1992) . This compartment is a functional organelle through which both vacuolar proteins and endocytosed a-factor receptor (Ste3p) pass en route to the vacuole (Piper et al., 1995) . To determine whether endocytosed a-factor receptor is transported through the prevacuolar compartment, we looked at receptor distribution in the vps27pep4 and vps2pep4 mutants that accumulate vacuolar proteins in this structure. The results obtained from both mutants were identical and the data for the vps2pep4 mutant are shown in Figure   lb . Before exposing the cells to a-factor, receptor was found on both the cell surface and in the prevacuolar compartment. After the addition of pheromone, receptor disappeared from the cell surface and was seen in one large perivacuolar dot, consistent with the idea that the surface receptor had been transported to the prevacuolar compartment. Although we have not performed double labeling of Ste2p and a vacuolar protein to determine that they colocalize in the same structure in vps cells, this result is in agreement with the previous observation that the prevacuolar compartment corresponds to a late endocytic intermediate that is a point at which both endocytic and biosynthetic pathways intersect (Piper et al., 1995) .
Confocal microscopy was used to confirm that the small peripheral and large perivacuolar staining of receptor observed after a-factor addition corresponded to intracellular organelles. Immunofluorescence of wild-type cells was performed as for Figure 1 and the cells were visualized by using a confocal microscope. Figure 2a shows the staining of receptor in a 3D reconstruction and in a single slice or section through the same cell, both before and at various times after treatment of cells with a-factor. Before a-factor treatment, Ste2p was seen in small patches on the cell surface. Surface localization was confirmed by the ring of staining observed in the slice. Eight minutes after a-factor addition, receptor had moved into small intracellular compartments and a more brightly stained perivacuolar organelle. After 16 minutes, receptor had moved almost completely into the perivacuolar organelle. The slice pictures show that these compartments reside within the cell. Like end4, the end6 temperature-sensitive mutant is also unable to internalize a-factor at the nonpermissive temperature (Munn et al., 1995) . Confocal microscopy of end6 cells shows that, at the nonpermissive temperature, receptor was found to have a surface staining pattern exclusively, even at 16 min after exposure to a-factor.
The morphology of the large perivacuolar organelle was investigated in more detail by immunoelectron microscopy. Figure 2b shows electron micrographs of wild-type cells after 16 min of exposure to a-factor. In many cell profiles, electron-dense multivesicular membrane-bounded organelles were found next to the vacuole. Their appearance was similar to that of mammalian late endosome/prelysosome (Helenius et al., 1983) . Gold labeling was concentrated over these structures, indicating the presence of Ste2p. They were usually organized into large clusters that were similar in size to that of the bright perivacuolar bodies seen by immunofluorescence microscopy (0.5-1 mm). This, along with the similarity in intracellular location, indicates that these electron-dense organelles probably correspond to the perivacuolar organelles observed by light microscopy. To correlate the perivacuolar endocytic organelle with the early and late endocytic intermediates that have been identified by subcellular fractionation, we analyzed the transport of a-factor peptide under conditions similar to those used to detect its receptor by immunofluorescence. a-Factor is normally transported rapidly through an early and a late endosome to the vacuole where it is degraded. Transport of radiolabeled peptide through each endosome can be followed by the separation of endosomes by differential centrifugation and subsequent fractionation on Nycodenz gradients (Singer and Riezman, 1990) . The experiments, depicted in Figures 1 and 2 , that followed the transport of internalized a-factor receptors were performed on cells pretreated with cycloheximide to inhibit new receptor synthesis. We therefore examined the effect of cycloheximide on the transport of the internalized ligand radiolabeled a-factor. Cycloheximide at concentrations up to 100 jig/ml had no effect on the ability of cells to internalize a-factor (our unpublished data); however, surprisingly, the drug inhibited the rate of degradation of internalized peptide ( Figure 3a) . After a 5-min preincubation with 100 jig/ml cycloheximide, a-factor degradation was obviously retarded and longer preincubation (15 min) exacerbated the effect. The same effect was observed in cells treated with 10 ,tg/ml cycloheximide. As internalized ligand is degraded in the vacuole, this delay in degradation implied that transport of peptide between the plasma membrane and the vacuole was slower than in the absence of cycloheximide. Differential centrifugation of lysates prepared from cells that internalized a-factor in the presence or absence of cycloheximide showed that a-factor did accumulate in endosomes in the presence of the drug (Figure 3b ). During this type of experiment, vacuoles sediment rapidly and are collected after centrifugation at 7500 x g (P1 fraction), whereas endosomes are found in the Figure 1 (cont). Immunofluorescence localization of a-factor receptor during its transport through the endocytic pathway. The transport of a-factor receptor was visualized in cells after stimulating internalization by exposing cells to a-factor pheromone. At the times after addition of a-factor indicated, cells were fixed and Ste2p was detected by using affinity-purified Ste2p antiserum. Immunofluorescence microscopy of Ste2p expressed in pep4 (RH3089), end4pep4 (RH3387), and vps2pep4 (RH2401) cells. The pattern of Ste2p localization in each strain is shown both before exposure of cells to a-factor (no) and at 16 min after a-factor addition at 30°C. Notice that the receptor detected in the vps2pep4 mutant is in a compartment that lies immediately adjacent to the vacuole, not in the vacuole itself. pellet (P3 fraction) of a 100,000 x g centrifugation (Singer and Riezman, 1990) . In untreated cells, radiolabeled a-factor initially was found mostly in the P3 fraction. Sixty minutes after internalization, the radioactive ligand was recovered primarily in the P1 fraction. In contrast in the presence of cycloheximide, a-factor remained associated with the P3 fraction for much longer and was still found primarily in this pellet even after a 60-min internalization.
Early and late endosomes that have been collected in P3 can be separated from each other by fractionation on Nycodenz gradients. In the absence of cycloheximide, a-factor was found in both endosomal populations at early time points after internalization and was quickly transported out of both organelles. In cells treated with the drug, a-factor was also detected in both compartments at early time points but then accumulated in the late endosome fractions (Figure 3c ). Cycloheximide may delay transport from the late endosome to the vacuole. Alternatively, a-factor may normally disappear from the late endosome not only because of transport but also because of degradation by newly synthesized proteases that mix with the peptide in this organelle. Inhibiting the synthesis of new vacuolar proteins would then inhibit the degradation of a-factor in the late endosome. Regardless of the cause, almost all internalized a-factor was found in the late endosome 20 min after internalization. At 16 min after pheromone addition, immunofluorescence experiments showed that a-factor receptor accumulated in the large perivacuolar structure (Figures la and 2a) . Therefore, we suggest that this structure represents the yeast late endosome.
Because cycloheximide adversely affects transport of a-factor through the endocytic pathway, it is possible that Ste2p accumulates in an aberrant nonfunctional structure induced by cycloheximide and that this structure has physical characteristics similar to the late endosome. To determine whether internalized receptor is detected in a large prevacuolar structure even in the absence of cycloheximide, we performed immunofluorescence with anti-receptor antiserum on cells stimulated with a-factor in the absence of drug treatment (Figure 4 ). In the absence of cycloheximide, the receptor travels through structures similar in appearance to those observed in the presence of the drug. The large perivacuolar structure is clearly observed in these cells though not as prominently as in cells treated with cycloheximide. This is consistent with the observation that transport through this compartment is more rapid in the absence of cycloheximide. Because a-factor induces the expression of Ste2p, newly synthesized protein is observed in perinuclear structures that probably correspond to ER at later times after a-factor addition (e.g., at 16 min). An Active Early Secretory Pathway Is Required to Promote Membrane Traffic through the Endocytic Pathway To determine whether Sec proteins that function to mediate vesicle budding and fusion during transport through the biosynthetic pathway are required in the endocytic pathway, we analyzed the ability of sec mutants to internalize radiolabeled a-factor and transport it to the vacuole. We focused our attention on mutants that block ER -> Golgi transport because these mutations inhibit the first step of the secretory pathway that requires membrane transport and, therefore, potentially may affect multiple membrane transport events. Preliminary experiments indicated that none of the Sec proteins that are required for ER -> Golgi transport, specifically secl2, secl3, secl6, secl7, secl8, sec2O, sec2l, sec22, sec23, yptl, and sarl, are required for a-factor internalization (our unpublished data). Although at 37°C several of the sec mutants internalized a-factor more slowly and to a lesser extent than wildtype cells at the nonpermissive temperature, none of these mutants exhibited a severe defect such as that seen in endocytosis mutants (Raths et al., 1993; Munn and Riezman, 1994; Munn et al., 1995) . In contrast, all of the ER -> Golgi sec mutants showed a strong reduction in the rate of a-factor degradation at 37°C (Table  2) . To extend this observation, we chose to analyze only the most restrictive sec mutants. secl2 and secl8 cells do not grow at 32°C. To determine how severely the secretory pathway is inhibited at this temperature, we analyzed transport of the vacuolar protein CPY. Figure 5a shows a pulse-chase analysis of CPY performed on wild-type, secl2, and secl8 cells after a 5-min preincubation at 32°C. In wild-type cells, the core-glycosylated ER form of CPY (pl) observed after a 5-min pulse and 0-min chase had been almost completely converted to the mature vacuolar form after a 15-min chase. A small amount of the Golgi p2 form remained. In secl2 and secl8 cells, however, CPY remained exclusively in the ER form after a 15-min chase demonstrating a complete block in transport under these conditions. Figure 5b shows that a-factor internalization under the same conditions was similar in wild-type and secl2 cells and somewhat slower in secl8 cells. Degradation of internalized a-factor, however, was strongly inhibited in both secl2 and secl8 cells at 32°C (Figure 5c ). In this experiment, a-factor degradation products were difficult to detect even in wild-type cells (for another example, see Figure 5 ). In Figure 5c , degradation products are barely detectable in secl2 cells. They were, however, more pronounced in other experiments indicating that a small amount of degradation did occur in the secl2 mutant.
The observation that all of the ER -> Golgi Sec proteins were required for efficient a-factor degradation, including Secl2p, which is thought to reside exclusively in organelles of the early secretory pathway (Nakano et al., 1988; Nishikawa and Nakano, 1993) , suggested that ongoing membrane transport through the secretory pathway might be essential for efficient endocytic transport. To determine whether proteins that function at later stages of the secretory pathway are also necessary for endocytic transport, we tested the ability of sec mutants that block intraGolgi and Golgi -> plasma membrane transport to degrade a-factor. The sec7 mutation blocks intraGolgi transport and sec4 inhibits the fusion of Golgi-derived secretory vesicles with the plasma membrane. Assays that measured the transport of CPY or the secretion of the periplasmic protein invertase showed that each of these mutant proteins was completely inactivated after a 15-min preshift at 37°C (our unpublished data). Figure 6 shows the ability of wild-type, sec7, and sec4 cells to degrade a-factor under these conditions. Like secl2, the sec7 mutant was strongly affected in its ability to degrade internalized a-factor. The sec4 mutant, however, degraded a-factor nearly as rapidly as wild-type cells. Other sec mutants, sec5 and sec9, that block Golgi -> plasma membrane transport also degraded internalized a-factor normally (Table 2 ). These data show that the function of Sec proteins involved in ER --Golgi and intraGolgi transport are required for endocytic membrane transport. In contrast, the functions of the Sec4p, Sec5p, and Sec9p proteins that are required for Golgi --plasma membrane transport are not necessary for endocytic traffic.
Secl8p/NSF and the Early Secretory Pathway Are Required for Transport through the Early Endosome To test which stage of the endocytic pathway is inhibited in the secl2 and secl8 mutants, we isolated endosomes from mutant cells that had internalized a-factor at the nonpermissive temperature. Figure 7a shows the transport of a-factor through endosomes in wildtype and secl2 cells that had been preincubated at 32°C before the addition of pheromone. allowed to bind to the cells at 32°C, unbound peptide was removed, and bound peptide was chased through the endocytic pathway at the same temperature. In wild-type cells, a-factor was found in both early and late endosomes at early times after internalization and was chased rapidly from both endosomes. In secl2 cells, a-factor was found primarily in the early endosome at early time points and remained there for more than 1 h after internalization. A similar experiment was performed with secl8 cells; however, the preincubation step was eliminated because mutant Secl8 protein is inactivated very rapidly at 32°C. Wild-type and secl8 cells were allowed to bind radiolabeled a-factor on ice, unbound ligand was removed by centrifugation, and the cells were resuspended in 32°C medium to initiate the chase through the endocytic pathway. At the first time point (5 min), a-factor was found in about equal amounts in both early and late endosomes in wild-type cells. It was transported through both of these compartments by 30 min. In secl8 cells, radiolabeled peptide was found only in the early endosome at 5 min, no peptide was (Figure 3 cont.) centrifugation. The amount of radioactivity associated with each pellet fraction and the final supernatant fraction was measured and is depicted as a percentage of the radioactivity measured in the original lysate. The P1 fraction contained the vacuoles and most of the plasma membrane and the P3 fraction contained endosomes. (C) The P3 membrane pellet represented for each time point in B was loaded onto Nycodenz gradients to separate the early and late endosomal fractions. The y axis represents the cpm associated with each fraction. The early endosomes are found in fractions [8] [9] [10] [11] and the late endosomes are in fractions 4-7. The 0-min chase time point corresponds to "10 min after the initiation of pheromone internalization (see MATERIALS AND METHODS). detected in the late endosomal fractions, and it remained in the early compartment after a 60-min chase at 32°C (Figure 7b ). In addition, internalized a-factor in secl8 accumulated in a novel dense compartment (peak in fraction 12) at the later periods of chase. a-Factor found in this peak may be in an aberrant membrane generated only in mutant cells. Alterna- . After a-factor binding, cells were resuspended in 32°C medium and cell lysates were prepared from aliquots taken at the indicated times. Internalized a-factor extracted from the lysates was subjected to TLC to separate the intact (brackdegtbradedti et) and degraded (arrow) forms of the peptide. The 0-min time point corresponded to 10 min of internalization at which time "60% of the bound pheromone had been internalized in wild-type and secl2 cells and "40% of the bound pheromone had been internalized in secl8 cells.
tively, the a-factor found in this peak may reside in an early, as yet uncharacterized, endocytic intermediate that was not easily detectable in wild-type cells.
These data demonstrate that blocking ER -> Golgi transport in secl2 and secl8 mutants rapidly induces a severe retardation of membrane traffic through the early endosome. As mentioned above, it is unlikely that the Secl2 protein functions directly in the endocytic pathway. Secl8p, however, is a cytosolic/peripheral membrane protein and secl8 cells exhibited different phenotypes than the other sec mutants with respect to the endocytic pathway. secl8 cells internalized a-factor more slowly than wild-type cells and accumulated a-factor in a membrane-bounded compartment not observed in secl2 cells. These differences suggested that the phenotypes of the secl8 mutant may be due to a direct function of the Secl8 protein in the endocytic pathway and not simply to an indirect effect of inhibiting ER -> Golgi transport. To provide more evidence for this contention and to visualize the early endocytic compartment(s) that accumulated a-factor in secl2 and secl8 cells, we 'performed immunofluorescence microscopy with anti-Ste2p antiserum on wild-type and mutant cells preincubated for 5 min at 32°C. Figure 8a shows that in wild-type cells transport of the receptor upon a-factor binding occurred much as was seen at 30°C. secl2 cells exhibited a different phenotype under these conditions. After exposure to a-factor, receptor was transported to a perivacuolar compartment in some cells; however, there was also intense staining of small more peripheral compartments that persisted even 30 min after a-factor addition. Note that the receptor staining in secl2 cells resembles that seen in wild-type cells incubated at 15°C at early times after a-factor addition. The morphological data are consistent with results from endosome fractionation experiments indicating that membrane traffic through the early endosome is severely retarded in secl2 at the nonpermissive temperature. In this experiment, secl8 exhibited a different phenotype than secl2. Receptor internalized into secl8 cells at 32°C was seen in small vesicular structures distributed throughout the cytoplasm and never reached the perivacuolar late endosome. The endocytic phenotype of secl8 suggests that it acts before the block imposed by inhibiting the secretory pathway. In addition, the role of Secl8p/NSF in promoting the fusion of transport vesicles with their target membrane is consistent with a role for Secl8p in the fusion of primary endocytic vesicles with, or to form, an early endosome. If this proposal is true, the endocytic phenotype of secl8 should be epistatic to that of secl2 even though in the secretory pathway the opposite is true (Kaiser and Schekman, 1990) . To test this, we constructed a double mutant, secl2secl8, and visualized internalized receptor in the double mutant after addition of a-factor at 32°C. Figure 8b shows (Graham et al., 1993; Shah and Klausner, 1993; Vogel et al., 1993) . To test the effect of BFA on the yeast endocytic pathway, we assayed the ability of erg6 cells to internalize and degrade a-factor in the presence of the drug. Figure 9a shows that internalization of a-factor proceeded with wild-type kinetics even at concentrations of up to 250 ,ug/ml BFA. In contrast, a-factor degradation is completely inhibited by BFA (Figure 9b) .
To determine at which point the endocytic pathway is sensitive to BFA, we isolated and separated endosomes from erg6 cells that had internalized a-factor in the presence of BFA. After a 10-min internalization, a-factor was detected equally in early and late endosomes in untreated cells but was Early endosomes that mediate the transport of radiolabeled a-factor have been identified by subcellular fractionation (Singer and Riezman, 1990; SingerKruger et al., 1993) , and most likely correspond to the small peripheral elements that label with anti-receptor antibody at early time points in this study. Evidence that these peripheral structures are early endosomes comes from morphological and fractionation studies in the secl2 and secl8 mutants. In both cases, internalized a-factor accumulated at a restrictive temperature in organelles that cofractionated with early endosomes and, under similar conditions, the a-factor receptor was localized mainly at the periphery of the cells by immunofluorescence. As both a-factor and its receptor are internalized together, it is likely that they follow the same pathway to the vacuole. The early endosome may be heterogeneous in size or nature because the immunofluorescent labeling pattern seen in the secl2 and seci8 mutants was distinct. A recent study has demonstrated that the organelle that accumulates proteins en route to the vacuole in a subset of vps mutants is a functional prevacuolar intermediate (Piper et al., 1995) . Both endocytosed and newly synthesized vacuolar proteins pass through this compartment (Piper et al., 1995) . In this study we correlate the appearance of a-factor in the late endosome by subcellular fractionation with the accumulation of the a-factor receptor in a large perivacuolar compartment by immunofluorescence. Our results strongly suggest that this late endosome is the previously described prevacuolar compartmi ent.
The late endosomal compartment was visualized in more detail by immunogold labeling and its morphology is similar to what has been described for the late endosome in animal cells (Griffiths et al., 1988; McDowall et al., 1989) . In cross-section it appears to be multivesicular in nature with internal membranes. Also similar to the situation in animal cells, the late endosome is localized more toward the interior of the cell than early endosomes, but in yeast the compartment is near the vacuole rather than juxtanuclear. We have demonstrated that a-factor and its receptor accumulate in the early endosome in ER -> Golgi sec mutants at the nonpermissive temperature. It is unlikely that this observation reflects a direct requirement for most Sec proteins at the endosome as the localization of some of the proteins (e.g., Secl2p) is restricted to the organelles of the early secretory pathway. The need for an active biosynthetic pathway suggests that some molecule(s) must be continuously delivered into the endosomal system from the secretory pathway. Because delivery of this factor does not require the late secretory pathway, it may be transferred directly from the Golgi to the early endosome. This pathway has not been observed in yeast, but evidence for such a route exists in mammalian cells (Sariola et al., 1995 where it would be destroyed. Lipids, or proteins that modify them, have been shown to be important for several membrane trafficking steps in yeast, including vacuole biogenesis (Schu et al., 1993) , endocytosis (Munn and Riezman, 1994) , ER -* Golgi transport of glycosylphosphatidylinositol-anchored proteins (Horvath et al., 1994) , and exit from the Golgi (Cleves et al., 1991) . A phosphatidylinositide may be a lipid required at the early endosome as the PI-3 kinase, Vps34p, has been shown to be required for the efficient transport of internalized a-factor to the vacuole (Munn and Riezman, 1994) .
The requirement for continuous delivery of a molecule from the Golgi to endosomes to promote endocytic traffic ensures a tight coupling or balance between the secretory and endocytic pathways. This could be important in a cell such as yeast that expands its plasma membrane continuously during rapid growth and changes its growth rate depending on nutrient availability and temperature.
Molecular Mechanisms Involved in the Yeast
Endocytic Pathway Secl8p/NSF is required at multiple steps in the secretory pathway in both yeast and mammalian cells (Graham and Emr, 1991; Rothman and Orci, 1992) and is required for the fusion of early endosomes with each other in vitro (Diaz et al., 1989) . We have now shown that Secl8p is required in vivo for the forward progression of molecules from the plasma membrane to the vacuole in yeast. a-Factor internalized in a secl8 strain at the nonpermissive temperature is found in an endosomal compartment of the same density as the early endosome. Because ER -> Golgi transport is inhibited in the secl8 mutant and because we have shown that an active secretory pathway is necessary for efficient membrane transport from the early endosome, it could be that the requirement of Secl8p in the endocytic pathway is merely due to its activity in ER -> Golgi transport. This is probably not the case because the secl8 mutant exhibits a different endocytic phenotype than the other ER -> Golgi sec mutants and this phenotype is epistatic to the block imposed by inhibiting the secretory pathway. In secl8 cells incubated at the nonpermissive temperature, internalized a-factor receptor accumulates in many small peripheral vesicles, a staining pattern distinctly different from that observed in secl2 cells under the same conditions. Furthermore, in a secl2secl8 double mutant receptor accumulates in the same pattern as that observed for the secl8 single mutant, demonstrating that in the endocytic pathway Secl8p acts before the step at which input from the secretory pathway is required.
The role of Secl8p/NSF in secretion is to promote the fusion of transport vesicles with their target membranes, a process that occurs between two different types of membranes and has been referred to as heterotypic fusion. Some homotypic fusion events that occur between membranes of secretory organelles have been shown to be independent of Secl8p/NSF and to require a related protein known as Cdc48p/p97 (Acharya et al., 1995; Latterich et al., 1995; Rabouille et al., 1995) . However, Secl8p has been shown to be required for homotypic fusion in the endocytic pathway in cell-free systems in animal cells (Diaz et al., 1989 , Rodriguez et al., 1994 . In addition, Secl8p/NSF is required to mediate the homotypic fusion of vacuolar membrane that occurs during the in vitro reconstitution of vacuole inheritance in yeast (Mayer et al., 1996) . Our results are consistent with a function for Secl8p early in the endocytic pathway after internalization. Secl8p may promote the homotypic fusion of primary endocytic vesicles with each other to form a more mature early endosome or may be involved in the heterotypic fusion of primary endocytic vesicles with a preexisting early endosome. Another member of the Secl8/Ccd48/Pasl family of ATPases may also function in the endocytic pathway. The END13 gene that is required for efficient postinternalization endocytic membrane transport encodes such an ATPase (Stevenson and Riezman, unpublished data; GenBank accession no. U25843).
Treatment of mammalian cells with BFA drastically alters the morphology of their endocytic organelles. Internalization and recycling of receptors appear to continue in the presence of BFA. Other endocytic traffic events are disrupted by the drug, including the delivery of fluid-phase markers to the lysosome (Lippincott-Schwartz et al., 1991) and the transcytosis of IgA from the basolateral to the apical surfaces of MDCK cells (Hunziker et al., 1991) . Treatment of sensitive yeast with BFA causes a complete block in transport from the early endosome although there is no effect on the earlier internalization step. Immunofluorescence experiments indicate that BFA probably also alters the morphology of yeast endosomes (our unpublished data). BFA inhibits traffic through the early secretory pathway and this may be the explanation for its dramatic effect on endocytosis. It is likely though that BFA inhibits endocytic traffic directly. The effect of BFA on endocytosis is immediate and requires no preincubation of cells with the drug. In addition, BFA causes an absolute block in transport, no a-factor is degraded in the presence of BFA and peptide transport through the early endosome was prevented completely. This is in contrast to the effect seen by inhibiting the biosynthetic pathway in most of the sec mutants, in which traffic through the endosome is severely retarded but not completely inhibited.
BFA blocks the binding of cytoplasmic coat proteins that mediate vesicle budding to organelles. Coat complexes composed of COPI proteins have recently been shown to assemble onto endosomes in vitro in a BFAVol. 8, January 1997 sensitive manner, suggesting that these proteins participate in endosomal transport (Whitney et al., 1995) . In yeast, however, COPI proteins encoded by the RETI (a-COP) and SEC27 (f3'-COP) genes do not seem to be required for forward endocytic transport as a-factor degradation occurs normally in cells carrying mutations in these genes (Table 2 ). It is possible that another coat complex mediates endocytic transport.
